Dr. David R. Spigel, MD, FASCO presents Phase III ADRIATIC study at #ASCO24: consolidation durvalumab x 2y after chemoradiation for limited stage #SCLC. Balanced arms. >50% with PCI. Mostly daily radiation delivered.

Two standing ovations for lung cancer trials at the #ASCO24 plenary session! It’s an exciting time to be going into thoracic oncology!

Dr. Tina Cascone gives an important update on CheckMate 77T at the #ASCO24 oral abstract session. CheckMate 77T was a phase III study showing the addition of perioperative nivolumab to neoadjuvant chemo for resectable stage II/III NSCLC improved both EFS & pCR. Here, N2+ subset.

Just donated blood with American Red Cross of Colorado and Wyoming. They’re still in the Bruce Schroffel Conference Center and are taking walk-ins. If you’re at UCH and are able you should donate!

Let’s go!!! 🇩🇪🇩🇪🇩🇪 #euro2024 #gersco

Great start!! 🇩🇪🇩🇪🇩🇪 #gersco #euro2024

I (and millions of others) watched this man die on live TV 3 years ago and now he’s back at the Euros playing (and scoring) for his country. What an incredible story! Amazing work by the medical staff who brought him back! #EURO2024 #SVNDEN #NeverGiveUp

Welcome!

The first black cyclist to win a Tour stage and now the first to win a jersey! What an incredible moment for him and the sport of cycling!

For #WorldLungCancerDay, read about Ian Lancaster's journey to the CU Cancer Center, where his treatment for his lung cancer took a dramatic shift ⬇️ news.cuanschutz.edu/cancer-center/…

On #WorldLungCancerDay I salute all of the brave patients who have battled or are battling lung cancer, as well as all of the clinicians who care for them and the researchers working on better treatments. The work continues!

Great to be in San Diego for the first time for my first IASLC World Conference on Lung Cancer!

Morning run to Balboa Park ✅

Such a privilege to hear from this incredibly accomplished panel at the Young Investigator Workshop! IASLC #WCLC2024

If you’re at IASLC #WCLC2024 please come check out my poster! It’ll be up all day today in the Exhibit Hall. I’ll be there during the evening poster session (6:15-7:45pm) to answer questions and am happy to be contacted about my research anytime.

How refreshing to take a break and enjoy the company of the fabulous CU Cancer Center lung cancer team at #WCLC24. The jokes and pasta were on point!

#BR31 by Dr. Glen Goss, a herculean academic effort examining adjuvant durvalumab for resected lung cancer sadly negative, pushes the narrative even more toward neoadj/periop, the results by PD-L1 suggest this was a study destined to be negative. #lcsm #ESMO2024

We are pleased to share this article out today in Cancer Discovery on the preclinical development and proof-of-concept clinical activity of NVL-655 ✅4th-generation, #ALK-selective TKI ✅CNS-penetrant ✅Broad coverage of ALK fusions and mutations, including lorlatinib-refractory compound

🌟And here with the efficacy and safety data of #NVL655, ALK-selective, TRK-sparing and brain-penetrant 4G ALK TKI, from ALKOVE-1, presented today #ESMO24 by Alexander Drilon MD ✅ ORR 38% in heavily pretreated pts overall (1-5 prior ALK TKIs) ✅ ORR 35% in pts post-lorlatinib (in which

We are excited to share the updated efficacy&safety data of #Zidesamtinib (NVL-520), a next-generation ROS1-selective, TRK-sparing, brain-penetrant inhibitor in ROS1 fusion+ solid tumors, from the ongoing #ARROS1 global phase 1/2 trial, presented today #ESMO24 by Benjamin Besse